Ospedale Santo Spirito di Pescara
Welcome,         Profile    Billing    Logout  
 3 Trials 
4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Garufi, Carlo
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
TRIPP-FFX, NCT05466799: FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

Recruiting
2
80
Europe, RoW
FOLFIRINOX chemotherapy, Folinic Acid, 5-FU, Oxaliplatin, Irinotecan, OncoSil™, Phosphorous-32 microparticles
OncoSil Medical Limited
Locally Advanced Pancreatic Cancer
06/25
09/25
RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting
N/A
3000
Europe
Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.
Solid Tumours in Advanced Stages
10/26
10/26

Download Options